Navigation Links
Hypocalcemia in Medical Technology

First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival

... certain oncology indications. Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast ... by the prescriber prior to initiation of bisphosphonate treatment. hypocalcemia may occur with Reclast therapy. All patients with Paget's disease should ...

Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis

... certain oncology indications. Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast ... by the prescriber prior to initiation of bisphosphonate treatment. hypocalcemia may occur with Reclast therapy. In the Pivotal Fracture Trial an increased ...

New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis

... in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... cases, intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

... osteoporosis. Reclast is contraindicated in patients with hypocalcemia (low blood calcium), hypersensitivity to zoledronic acid and in women who ... already being treated with Zometa should not be treated with Reclast. hypocalcemia may occur with Reclast therapy. All patients with Paget's disease should ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

... Grade 4 lymphopenia, neutropenia and thrombocytopenia were observed in 1, 2 and 2 patients, respectively. Grade 1-3 anemia, nausea/vomiting and hypocalcemia were observed in 18, 1, and 3 patients, respectively. “Myelosuppression, particularly neutropenia, is a substantial clinical problem in ...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...
Other Contents
(Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and segments the ... forecast. The well intervention services market in Europe is estimated ... billion by 2018, at a CAGR of 7% from 2013 ... Well Intervention Market report, to get an idea of the ... segmentation in the Europe well intervention market, and is supported ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Alliance ... nation’s only non-profit dedicated exclusively to cell and ... Joshua Corday has joined the organization as Senior ... professional with deep experience securing gifts and addressing ... as Annual Giving Director for NewYork Presbyterian Hospital/Columbia ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
Other TagsOther Tags